title: Hypermetabolic subcutaneous fat in patients on highly active anti-retroviral therapy treatment: Subtle finding with implications.
abstract: Lipodystrophy (LD) is a serious complication of highly active anti-retroviral therapy, characterized by peripheral fat wasting, central adiposity and metabolic changes. Since the disfiguration caused by LD is permanent, the focus of management is on early detection to arrest progression. We report a case where ancillary finding of increased fluorine-18 fluoro-2-deoxyglucose (F-18 FDG) uptake in the sub-cutaneous fat helped early detection of LD and led to early intervention to arrest progression. Though F-18 FDG positron emission tomography/computed tomography scan is not recommended to diagnose LD, conscious reporting of this finding when present can greatly influence patient management.
authors.affiliation: Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Parel, Mumbai, India.
authors.forename: Anand
authors.initials: A
authors.lastname: Zade
authors.forename: Venkatesh
authors.initials: V
authors.lastname: Rangarajan
authors.forename: Nilendu
authors.initials: N
authors.lastname: Purandare
authors.forename: Sneha
authors.initials: S
authors.lastname: Shah
authors.forename: Archi
authors.initials: A
authors.lastname: Agrawal
authors.forename: Ashish
authors.initials: A
authors.lastname: Jha
authors.forename: Mukta
authors.initials: M
authors.lastname: Kulkarni
keywords: Fluoro-2-deoxyglucose uptake in human immunodeficiency virus; highly active anti-retroviral therapy; lipodystrophy
references.citation: Clin Nucl Med. 2009 Oct;34(10):731-3
references.pmid: 19893417
references.citation: Clin Nucl Med. 2008 Nov;33(11):809-10
references.pmid: 18936624
references.citation: Lancet. 2003 Mar 1;361(9359):726-35
references.pmid: 12620736
references.citation: Eur J Nucl Med Mol Imaging. 2009 Jul;36(7):1176-84
references.pmid: 19350235
references.citation: Nucl Med Commun. 2009 Jan;30(1):41-7
references.pmid: 19306513
references.citation: Ann Nucl Med. 2011 Oct;25(8):536-46
references.pmid: 21674240
references.citation: J Acquir Immune Defic Syndr. 2002 Feb 1;29(2):117-21
references.pmid: 11832679
references.citation: AIDS. 2004 Dec 3;18(18):2430-2
references.pmid: 15622321
references.citation: South Afr J HIV Med. 2009 Dec;10(4):76-80
references.pmid: 20706598
references.citation: Eur J Nucl Med Mol Imaging. 2009 Apr;36(4):640-7
references.pmid: 19082590
references.citation: J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):562-8
references.pmid: 19561519
references.citation: Antivir Ther. 2007;12(8):1247-54
references.pmid: 18240864
references.citation: Nucl Med Commun. 2010 Apr;31(4):311-4
references.pmid: 20145581